Cytoprotective agents against ferroptosis
DHMBA inhibits intracellular iron and lipid ROS to protect renal tubular cells from ferroptosis, effectively mitigating kidney damage in diabetic nephropathy models and improving renal function.
JP2026084237APending Publication Date: 2026-05-21WATANABE OYSTER LAB +1
Patent Information
- Application Number
- JP2024196430
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-11-11
- Publication Date
- 2026-05-21
AI Technical Summary
Technical Problem
Existing treatments are inadequate in addressing ferroptosis-induced cell death in renal tubular cells, which is a form of iron-dependent lipid peroxidation linked to oxidative stress and mitochondrial dysfunction, contributing to kidney diseases.
Method used
A cytoprotective agent containing 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) is developed to inhibit intracellular iron and lipid ROS accumulation, thereby suppressing ferroptosis in renal tubular cells.
Benefits of technology
DHMBA effectively reduces ferroptotic cell death by lowering intracellular iron and lipid ROS levels, improving renal function and reducing markers of kidney damage in diabetic nephropathy models and human renal tubular cells.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026084237000001_ABST
Abstract
The present invention aims to provide a cytoprotective agent against ferroptosis that contains DHMBA as an active ingredient, by verifying the effect of DHMBA in suppressing ferroptotic cell death using DN model mice and human renal tubular cells HK-2, for each useful agent containing DHMBA as an active ingredient. [Solution] The present invention provides a cell agent for ferroptosis that has a cytoprotective effect against ferroptosis, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Anti-inflammatory agent
JP2024104803A